Amendments to the Claims:

The following listing of claims replaces all prior versions and listings of claims in the application:

1-30 (canceled)

31. (Presently amended) A glycoconjugate produced by ~~the~~ a method ~~of claim 20~~ comprising:

(a) providing a heterogenous population of *Neisseria meningitidis* serogroup B capsular oligosaccharide (MenB OS) derivatives in which sialic acid residue N-acetyl groups are replaced with N-acyl groups;

(b) obtaining a substantially homogenous group of MenB OS derivatives from the population of (a) wherein said group of MenB OS derivatives has an average Dp of about 10 to 20;

(c) introducing a reactive group at a reducing end of the derivatives obtained in step (b) to provide single end-activated MenB OS derivatives; and

(d) covalently attaching the end-activated MenB OS derivatives to a carrier molecule to provide a MenB OS glycoconjugate comprising substantially homogenous sized MenB OS moieties.

32. (Presently amended) A glycoconjugate produced by ~~the~~ a method ~~of claim 27~~ comprising:

(a) providing a heterogenous population of *Neisseria meningitidis* serogroup B capsular oligosaccharide (MenB OS) derivatives in which sialic acid residue N-acetyl groups are replaced with N-propionyl groups;

(b) obtaining a substantially homogenous group of MenB OS derivatives from the population of (a) wherein said MenB OS derivatives have an average Dp of about 12 to 18;

(c) introducing a reactive group at a reducing end of the derivatives obtained in step (b) to provide single end-activated MenB OS derivatives; and

(d) covalently attaching the end-activated MenB OS derivatives to a CRM_{197} bacterial toxoid carrier molecule to provide a MenB OS/CRM_{197} toxoid glycoconjugate comprising substantially homogenous sized MenB OS moieties.

33-42. (Canceled)

43. (New) The glycoconjugate of claim 31, wherein the reactive group introduced in step (c) comprises an active ester group.

44. (New) The glycoconjugate of claim 31, wherein the sialic acid residue N-acetyl groups of the MenB OS derivatives are replaced with N-propionyl groups.

45. (New) The glycoconjugate of claim 44, wherein the carrier molecule is a bacterial toxoid.

46. (New) The glycoconjugate of claim 45, wherein the carrier molecule is a nontoxic mutant bacterial toxoid.

47. (New) The glycoconjugate of claim 31, wherein the MenB OS derivative has an average Dp of about 12 to about 18.

48. (New) The glycoconjugatge of claim 31, wherein the MenB OS derivative further comprises a C3-C16 long-chain aliphatic lipid covalently attached thereto.

49. (New) The glycoconjugate of claim 32, wherein the MenB OS derivative further comprises a C3-C16 long-chain aliphatic lipid covalently attached thereto.